New research about the dying brain suggested the line between consciousness and death may not be distinct. (The Guardian)
A single fecal microbiota transplantation induced mild but sustained effects on motor symptoms in early Parkinson’s disease. (eClinical Medicine)
A new California bill aimed to ban paraquat, which has been tied to Parkinson’s risk. (Mother Jones)
An analysis using data from the FDA’s Adverse Event Reporting System suggested a possible link between anti-diabetic weight loss-inducing drugs and multiple sclerosis. (Therapeutic Advances in Neurological Disorders)
Prophylactic seizure treatment after mild and moderate traumatic brain injury was associated with a small reduced risk of early post-traumatic seizures. (JAMA Neurology)
Targeting KCNJ2 may reduce acute neuronal death after brain injury, a study in mice and brain organoids suggested. (Cell Stem Cell)
The NFL and its players’ association approved eight new position-specific helmets to help reduce head impact. (AP)
BrainStorm Cell Therapeutics said the FDA agreed to a protocol for a phase IIIb trial of investigational debamestrocel (NurOwn) for amyotrophic lateral sclerosis (ALS). Last year, FDA advisors overwhelmingly rejected the treatment based on phase III study results.
The brain-computer interface (BCI) company Synchron announced the launch of a BCI registry and is preparing to recruit patients for a large-scale clinical trial. (Reuters)
Epilepsy patients benefited from structured seizure action plans, new research showed. (Neurology Clinical Practice)
The Wall Street Journal looked at what people can do in midlife to prevent or delay future dementia.
Please enable JavaScript to view the